Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancerBOTHELL, Wash ...

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the ...
PharmiWeb

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
Cantech Letter

Perimeter Medical Imaging AI Announces LIFE Financing and Concurrent Private Placement

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES/ TORONTO and DALLAS, April 21, 2026 /CNW/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) ...
BioSpace

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...
TMCnet

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research ...

Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, is presenting new preclinical data demonstrating the strong anti-tumor ...
Al Bawaba

Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate

Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s ...

Synthetic Design Lab Unveils First Advanced Logic-Gated ADC at AACR 2026, Achieving >=10X Improvement in Targeted Cancer Cell Killing

SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...

Ten foods to boost your iron levels

Iron has a busy job to do in our bodies. It maintains healthy red blood cells that carry oxygen around the body, and it’s ...

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company focused on developing therapies that harness the patient’s innate immune system, today announces new preclinical ...
Pharmabiz

Samsung Bioepis initiates phase 1 trial for SBE303, nectin-4 targeting antibody-drug conjugate candidate

Samsung Bioepis initiates phase 1 trial for SBE303, nectin-4 targeting antibody-drug conjugate candidate: Incheon, Korea Samsung Bioepis ...